NCT04087954

Evaluation the Impact of Self-Stigma Reduction Program on Psychosocial Outcomes Among People Diagnosed With Schizophrenia

Completed NA Last updated 12 September 2019

What this trial tests

NA trial testing Stigma reduction program in Stigmatization in 278 participants. Completed in 22 December 2018.

Timeline

1 November 2017

Primary endpoint
22 December 2018

22 December 2018

Quick facts

Lead sponsor	Fakeeh College for Medical Sciences
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	health services research
Enrollment	278
Start date	1 November 2017
Primary completion	22 December 2018
Estimated completion	22 December 2018
Sites	1 location across Jordan

Drugs / interventions tested

• Stigma reduction program

Conditions studied

• Stigmatization — all drugs for Stigmatization →

Sponsor

Fakeeh College for Medical Sciences

Who can join

18 and older, any sex, with Stigmatization. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Backgrounds: Research evidence suggests that people diagnosed with schizophrenia (PDwS) experience higher level of stigma compared with other forms of mental illness, and they are prone to internalize stereotype, which exacerbates severity of psychiatric symptoms, reduces their psychosocial treatment adherence. The purpose of the study to evaluate the effectiveness of stigma reduction program on the perceived stigma, psychiatric symptoms, compliance with psychosocial intervention and self-efficacy.

Methods: A randomized controlled trial was conducted from November 2017 to December 2018 with 278 PDwS. Participants aged 18 years or older with DSM-IV schizophrenia or schizoaffective disorder, from four outpatient mental health clinics in Jordan, were randomly assigned to receive 13 sessions of a booklet form of stigma reduction program (n = 140) (psycho-education, cognitive behavioural therapy and social skills training), and treatment as usual \[TAU\] (intervention, n = 140), or TAU (control, n = 138). Participants were assessed at baseline, immediately post-intervention (post-treatment1) and at six months follow-up. The primary outcome measure was change in stigma perception. Secondary outcomes were psychiatric symptoms, compliance with psychosocial interventions and self-efficacy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Evaluation of the impact of a self-stigma reduction programme on psychosocial outcomes among people with schizophrenia spectrum disorder.
   Hasan AA, Alasmee N. · · 2022 · cited 6× · PMID 34517747 · DOI 10.1080/09638237.2021.1922628